$4.49 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 106 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $39,746,100 | – | 734,000 | +100.0% | 0.89% | – |
| LUNG | New | PULMONX CORP | $26,862,231 | – | 2,402,704 | +100.0% | 0.60% | – |
| New | DOCGO INC | $26,460,350 | – | 3,059,000 | +100.0% | 0.59% | – | |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $23,060,100 | – | 2,765,000 | +100.0% | 0.51% | – |
| New | VENTYX BIOSCIENCES INC | $20,669,500 | – | 617,000 | +100.0% | 0.46% | – | |
| VKTX | New | VIKING THERAPEUTICS INC | $18,731,250 | – | 1,125,000 | +100.0% | 0.42% | – |
| GH | New | GUARDANT HEALTH INC | $18,259,737 | – | 778,999 | +100.0% | 0.41% | – |
| New | ROIVANT SCIENCES LTD | $12,915,000 | – | 1,750,000 | +100.0% | 0.29% | – | |
| NVTA | New | INVITAE CORP | $12,520,854 | – | 9,274,707 | +100.0% | 0.28% | – |
| New | MINERALYS THERAPEUTICS INC | $11,416,469 | – | 729,021 | +100.0% | 0.26% | – | |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $11,191,119 | – | 1,831,607 | +100.0% | 0.25% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $10,642,710 | – | 2,823,000 | +100.0% | 0.24% | – |
| VERA | New | VERA THERAPEUTICS INCcl a | $10,088,000 | – | 1,300,000 | +100.0% | 0.22% | – |
| New | STRUCTURE THERAPEUTICS INCsponsored ads | $8,921,250 | – | 375,000 | +100.0% | 0.20% | – | |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $7,527,000 | – | 650,000 | +100.0% | 0.17% | – |
| BLUE | New | BLUEBIRD BIO INC | $6,916,500 | – | 2,175,000 | +100.0% | 0.15% | – |
| New | ORCHARD THERAPEUTICS PLCspon ads new | $1,697,828 | – | 316,169 | +100.0% | 0.04% | – | |
| New | SIENTRA INC | $15,400 | – | 10,000 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.